The Far Side of Resistance to RAS Inhibitors.

IF 29.7 1区医学 Q1 ONCOLOGY

Cancer discovery Pub Date : 2024-11-01 DOI:10.1158/2159-8290.CD-24-1153

Michelangelo Marasco, Sandra Misale

引用次数: 0

Abstract

In this issue, four articles highlight the critical role of nongenetic mechanisms and cell plasticity in mediating resistance to different classes of RAS inhibitors in pancreatic ductal adenocarcinoma and non-small cell lung cancer. See related article by Benitz et al., p. 2162 See related article by Dilly et al., p. 2135 See related article by Araujo et al., p. 2183 See related article by Singhal et al., p. 2122.

查看原文本刊更多论文

RAS 抑制剂耐药性的远方

本期有四篇文章强调了非遗传机制和细胞可塑性在胰腺导管腺癌和非小细胞肺癌对不同类别 RAS 抑制剂产生耐药性方面的关键作用。见 Benitz 等人的相关文章，第 2162 页见 Dilly 等人的相关文章，第 2135 页见 Araujo 等人的相关文章，第 2183 页见 Singhal 等人的相关文章，第 2122 页。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.